Biopharmaceuticals market, estimated at US $199.7 billion globally in 2013, is further projected to reach US $497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (mAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US $51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US $56.3 billion, and further expected reach a projected US $144.5 billion by 2020.
The broad therapeutic applications of biopharmaceuticals commercialized so far are for some types of cancer, arthritis, diabetes (treated by insulin), blood diseases and anemia (treated by erythropoietin), and hemophilia (treated by blood clotting factors).Indus Gene is planning to produce insulin (Over the next 20 years, the WHO predicts that worldwide insulin sales will grow from $12 B to $54 B) and erythropoietin (world market of $6 B). The Company has the advantage of having senior scientists with wide exposure to US biotech industry.